Our findings that PGE2 can be suppressed in nevi (including BRAF-mutant nevi) in subjects at increased risk for melanoma suggest that PGE2 in nevi may be a useful biomarker and tissue target in future melanoma chemoprevention studies. Here, BRAF is linked to melanoma.